HD-OPM Archive
Topics › LDL, ApoB & lipid panel

Evolving LDL-C management (JAHA 2023): risk categories, thresholds and treatment goals

Gokhan Can · Nov 25, 2023 · ♥ 8 reactions · 11 comments · original Facebook post
LDL, ApoB & lipid panelGuidelines, policy & public health
AI summary & key facts

Summarizes a 2023 JAHA review of personalized LDL-C management, giving risk categories from low to very high and the LDL goals for each. High-risk patients should reduce LDL at least 50% to below 70 mg/dL, while very-high-risk patients should aim below 55 mg/dL, or below 40 after recurrent events on statins.

Evolving Management of Low‐Density Lipoprotein Cholesterol (2023)

(The linked document is an excellent overview of current best practices. Please read the relevant sections to understand what is optimal in your specific situation. Sharing a summary down below.)

Risk Categories:

LDL-C Treatment Thresholds/Goals:

Treatment Recommendations:

The guidelines emphasize early risk assessment and treatment to prevent first and recurrent ASCVD events across a continuum of risk. Combination therapy is key for high risk patients needing significant LDL-C lowering.

Paper · JAHA · 2023Evolving Management of Low‐Density Lipoprotein Cholesterol: A Personalized Approach to Preventing Atherosclerotic Cardiovascular Disease Across the Risk ContinuumManagement of elevated low‐density lipoprotein cholesterol (LDL‐C) is central to preventing atherosclerotic cardiovascular disease (ASCVD) and key to reducing the risk of ASCVD events. Current guidelines on the management of blood cholesterol recommend statins as first‐line therapy for LDL‐C reduction according to an individual's ASCVD risk and baseline LDL‐C levels. The addition of nonstatin lipid‐lowering therapy…ahajournals.org

Research cited

#ascvd#statins#bempedoicacid#cholesterol#diabetes#ezetimibe#pcsk9#guidelines
← newer: A balanced look at the ketogenic diet: anti-inflammatory potolder: Meta-analysis: lipid-lowering therapy regresses coronary pla →